At Abiomed's European headquarters in Aachen, Germany, Impella heart pumps have been developed and produced for more than 20 years to stabilize and recover the human heart. The single access procedure ...
A third-party randomized trial from King’s College London is being cited as the reason Johnson & Johnson’s Impella usage has ...
Abiomed Inc.ABMD recently announced that its Impella 2.5 heart pump has received FDA Pre-Market Approval (PMA) for use in high risk percutaneous coronary intervention (PCI) procedures. Notably, ...
Impella 2.5 is the Only FDA-Approved Percutaneous Hemodynamic Support Device Determined to be Safe and Effective for the High Risk PCI Indication DANVERS, MA – Abiomed, Inc., a leading provider of ...
Over 3,000 U.S. Patients Have Received Higher Flow Impella CP DANVERS, Mass., (GLOBE NEWSWIRE) -- Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported that ...
The Heart Hospital of Northwest Texas Healthcare System has been recognized by Abiomed for its achievement of 200 Impella procedures, according to a news release. This life-changing procedure has ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...
Abiomed was founded in 1981 with the bold mission to create the world's first artificial heart. While decades of hard work ultimately resulted in a regulatory thumbs-up for the company's AbioCor ...
AACHEN, Germany--(BUSINESS WIRE)--Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results